Subscribe
official_portrait_of_michelle_donelan_mp
(Photo source UK Parliament website. Used under Creative Commons).
7 September 2023FeaturesBig PharmaSarah Speight

‘One of the most positive announcements since Brexit’: UK lawyers react to new Horizon funding deal

Today, the British scientific community woke to the news that the UK has finally rejoined Horizon Europe, the European Union’s €95.5 billion ($102 billion) research funding programme.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Horizon crosses the Atlantic to acquire Raptor for $800m
14 September 2016   Irish drugs producer Horizon Pharma has entered into a definitive agreement with Raptor Pharmaceuticals in which Horizon will buy the US biopharmaceutical company for $800 million.
Americas
Horizon agrees licensing deal over anti-inflammatory drug
18 September 2015   Drugs company Horizon Pharma has agreed to settle a patent dispute centring on a proposed generic version of its anti-inflammatory drug Pennsaid.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Horizon crosses the Atlantic to acquire Raptor for $800m
14 September 2016   Irish drugs producer Horizon Pharma has entered into a definitive agreement with Raptor Pharmaceuticals in which Horizon will buy the US biopharmaceutical company for $800 million.
Americas
Horizon agrees licensing deal over anti-inflammatory drug
18 September 2015   Drugs company Horizon Pharma has agreed to settle a patent dispute centring on a proposed generic version of its anti-inflammatory drug Pennsaid.

More on this story

Americas
Horizon crosses the Atlantic to acquire Raptor for $800m
14 September 2016   Irish drugs producer Horizon Pharma has entered into a definitive agreement with Raptor Pharmaceuticals in which Horizon will buy the US biopharmaceutical company for $800 million.
Americas
Horizon agrees licensing deal over anti-inflammatory drug
18 September 2015   Drugs company Horizon Pharma has agreed to settle a patent dispute centring on a proposed generic version of its anti-inflammatory drug Pennsaid.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
Foley & Lardner adds litigation and transaction expert in New York
‘AI curious’ counsel at AZ, Novartis weigh risks and benefits
Trump’s return sparks calls for pro-patent agenda